Two Sigma Advisers
ELDN icon

Two Sigma Advisers’s Eledon Pharmaceuticals ELDN Stock Holding History

Two Sigma Advisers’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,100
Closed -$17.9K – 2537
2023
Q3 		$17.9K Sell
13,100
-9,900
-43% -$13.2K ﹤0.01% 2327
2023
Q2 		$31.5K Sell
23,000
-2,100
-8% -$4.38K ﹤0.01% 2303
2023
Q1 		$59.2K Sell
25,100
-500
-2% -$1.34K ﹤0.01% 2434
2022
Q4 		$58.4K Sell
25,600
-16,600
-39% -$41K ﹤0.01% 2349
2022
Q3 		$116K Sell
42,200
-2,800
-6% -$8.92K ﹤0.01% 2289
2022
Q2 		$110K Sell
45,000
-39,011
-46% -$119K ﹤0.01% 2381
2022
Q1 		$331K Sell
84,011
-43,589
-34% -$169K ﹤0.01% 2178
2021
Q4 		$563K Buy
127,600
+11,700
+10% +$59.2K ﹤0.01% 1861
2021
Q3 		$716K Buy
115,900
+37,600
+48% +$263K ﹤0.01% 1771
2021
Q2 		$619K Buy
78,300
+60,200
+333% +$568K ﹤0.01% 1850
2021
Q1 		$194K Buy
+18,100
New +$273K ﹤0.01% 2358

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JE
JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return

Two Sigma Advisers's ELDN Position: Q4 2023 in Review

Two Sigma Advisers sold out of Eledon Pharmaceuticals (ELDN) in Q4 2023, closing a stake of 13,100 shares — an estimated $17.9K sold.

Two Sigma Advisers first reported a position in ELDN in Q1 2021 and held it in 11 quarters. The position peaked at $716K in Q3 2021. 29 funds tracked by Wall St. Rank hold ELDN as of Q4 2023.

  • Two Sigma Advisers reported no remaining Eledon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 13,100 Eledon Pharmaceuticals shares in Q4 2023, an estimated $17.9K.
  • Two Sigma Advisers first reported a position in Eledon Pharmaceuticals in Q1 2021 and held it in 11 quarters.
  • Two Sigma Advisers's Eledon Pharmaceuticals position peaked at $716K in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2023.

Based on Two Sigma Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.